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1. Introduction 
Chromosomal aberration is a phenomenon occurring relatively commonly in the 
development process. Chromosomal aberration is known to have various causes, and its 
frequency has been reported to vary particularly according to maternal age. Though 
different among reports, the frequency was around 0.6-0.8% in analysis with all childbirths1 
and around 2-3% in case childbirths were reclassified based on maternal age of 35.2 In 
addition, the frequency increased when the maternal age was relatively young, artificial 
insemination was used, etc.3 Spontaneous abortion related to such chromosomal aberrations 
occurs usually in the first trimester, and consequently, the prevalence of trisomy 21, 18 and 
13 decreases with the advance of gestational age.4 Chromosomal aberrations that can be 
found in prenatal diagnosis are largely divided into aneuploidy, structural aberration, 
mosaicism, uniparental disomy, small defect, etc., and additionally, there can be marker 
chromosomes. Marker chromosomes are observed in around one out of 1000 cases of 
chromosomal analysis, and are known to be related to old maternal age.5 It is reported that 
around 80% of marker chromosomes detected are new ones, and 13% of marker 
chromosomes are associated with physical abnormalities or cognitive disorders.6 
The frequency and type of chromosomal aberration are known to be different depending on 
the time of evaluation, population group under the analysis of structural chromosomal 
aberration, and the banding level of the laboratory performing cytogenetic evaluation.7 
Thus, it is increasingly important to conduct adequate prenatal genetic screening and 
analyze its results properly. Among chromosomal aberrations detected in pregnant women 
who received amniocentesis because of their age, 64% were trisomy (21% trisomy 21), 11% 
translocation, 17% sex chromosomal aberration, and 8% other types of chromosomal 
aberration.2 Thus, considering the increasing number of old age pregnancies in Korea, 
careful attention should to paid in analyzing the results of prenatal genetic tests. Thus, this 
study purposed to discuss how to analyze the results of maternal serum marker tests and 
sonography used in prenatal genetic evaluation.  
2. Maternal serum screening 
2.1 Alpha fetoprotein 
Brock and Sutcliffe 2 found in 1972 that the level of alpha fetoprotein in amniotic fluid 
increased when the fetus had a neural tube defect, and from the 1980s, the maternal serum 
alpha fetoprotein test began to be used for screening fetal anomalies in pregnant women. 
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Alpha fetoprotein, which is glycoprotein, is produced in the yolk sac in the early stage, and 
later in the fetal gastrointestinal tract and liver. A small portion of alpha fetoprotein in fetal 
serum may be discharged to urine and amniotic fluid, and it may diffuse through the fetal 
membrane and the placenta and enter maternal serum. Whereas the alpha fetoprotein level 
in fetal serum and amniotic fluid increases until 13 week and then decreases thereafter, the 
level in maternal serum increases continuously until 32 week because the size of the fetus 
keeps growing.8 Between 16-20 week of gestational age, the level of alpha fetoprotein in 
maternal serum is only around 1/100,000 of that in fetal serum. 
2.1.1 Analysis of serum alpha fetoprotein data 
As is known, the concentration of alpha fetoprotein in maternal serum or amniotic fluid is 
measured as a test for screening fetal neural tube defects. When the measurements of alpha 
fetoprotein are analyzed, we should be careful not to attach clinical importance to absolute 
values. It is because the test method of each laboratory or company may seem to have been 
stabilized by itself, but absolute values from the method are often different from those 
obtained by other laboratories or test methods. For this reason, the measurements of alpha 
fetoprotein are often reported as the multiples of the median (MoM). A median is the value 
in the middle when result values are put in order of size, so it can reduce errors and allow 
the comparative analysis of result values without being influenced by laboratory or test 
method.  
On the other hand, the measurements of alpha fetoprotein in maternal serum can be affected 
not only by multiple pregnancy and gestational age but also by maternal weight, diabetes, 
race, etc.9,10, so these factors should be confirmed before the analysis of such measurements. 
Because the absolute level of serum alpha fetoprotein rises along with gestational age8, 
underestimated gestational age is the most common cause of increased alpha fetoprotein 
concentration. In such a case, we can avoid unnecessary additional tests by correcting 
gestational age and recalculating the median. 
2.1.2 Causes of increased alpha fetoprotein in maternal serum 
Fetal anomalies  
The rise of the alpha fetoprotein level in maternal serum is often accompanied by fetal 
anomalies. This is not because of a special function of alpha fetoprotein but because fetal 
tissue leaks to amniotic fluid due to neural tube defect, abdominal wall defect, 
sacrococcygeal teratoma, cystic hygroma, skin defect, etc. and, as a result, an increasing 
amount of alpha fetoprotein flows into amniotic fluid and maternal serum11 or because 
alpha fetoprotein is not reabsorbed but discharged to urine due to fetal kidney anomaly.12  
In fetal neural tube defect, alpha fetoprotein exudes through exposed nervous tissue, so the 
level of alpha fetoprotein in maternal serum is relatively higher in spina bifida aperta or 
anencephaly than in spina bifida occulta. In most laboratories, those whose median alpha 
fetoprotein level in maternal serum is over 2.0-2.5 are classified into a high-risk group of 
fetal neural tube defect. When median 2.5 was used, spina bifida aperta was detected at a 
detection rate of 80% and the false positive rate was 3-4%.13  
The anomaly found second most commonly to neural tube defect in alpha-fetoprotein 
screening is abdominal wall defect. Particularly in case of gastroschisis, organs removed out 
of the abdominal cavity contact amniotic fluid directly, and therefore, the alpha fetoprotein 
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level tends to be higher than that in omphalocele.11 Maternal serum alpha fetoprotein 
screening detects around 85% of gastroschisis and around 50 % of omphalocele.11 
Placental abnormalities 
Because the concentration of alpha fetoprotein in fetal serum is 100,000 times higher than 
that in maternal serum8, even a small inflow of fetal blood increases the fetoprotein level in 
maternal serum rapidly. In case of chorioangioma in the placenta and hemangioma in the 
umbilical cord, fetal serum exudes into amniotic fluid and the maternal body due to mass 
bleeding14, and in case of placenta accreta, placental infarct, etc. as well, alpha fetoprotein 
increases in the same way.16 
2.2 Maternal serum test for aneuploidy screening 
2.2.1 Second trimester multiple marker screening test 
In 1984, Merkatz et al.16 found that the risk of Down syndrome was high when the level of 
serum alpha fetoprotein was low during the second trimester, but this finding alone was not 
sufficient for using alpha fetoprotein as an accurate Down syndrome marker.16 Later, double 
marker test that added human chorionic gonadotropin (hCG) test, and triple test that added 
also estriol (E3) to the double test were introduced as Down syndrome screening tests in the 
second trimester.18 Recently, quad test that added inhibin A was developed18 for higher 
accuracy of screening. The mean median (MoM) of each marker in trisomy 21 and 18 is 
presented in Table 1. There were large-scale prospective studies that compared accuracy 
among a number of multiple markers in the U.K. (Serum, Urine and Ultrasound Screening 
Study; SURUSS)19 and the U.S. (First and Second Trimester Evaluation of Risk for Fetal 
Anueploidy; FASTER),20 and in both studies the detection rate of quad markers was 
reported to be 81 %. Table 2 summarized the Down syndrome detection rates of multiple 
markers from the two studies. 
 
Aneuploidy AFP hCG uE3 Inhibin A 
Trisomy 21 0.74 * (↓) 2.05 * (↑) 0.70 * (↓) 2.548 * (↑) 
Trisomy 18 0.65** (↓) 0.32** (↓) 0.42** (↓) - 
AFP, ┙-fetoprotein; hCG, human chorionic gonadotropin; uE3, unconjugated estriol 
* Modified from the results of the FASTER trial 
** Modified from the results of Benn PA et al. Obstet Gyenecol 1999;93:707-11.  
Table 1. The mean MoM (multiples of the median) values for the second trimester maternal 
serum quad markers.  
 
  
Detection rate at a 5% false-
positive rate 
  SURUSS19 FASTER20 
Double markers AFP + hCG 66% - 
Triple markers AFP + hCG + uE3 74% 70% 
Quad markers AFP + hCG + uE3 + inhibin A 81% 81% 
AFP, ┙-fetoprotein; hCG, human chorionic gonadotropin; uE3, unconjugated estriol 
Table 2. The detection rate of second trimester serum markers for Down syndrome. 
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2.2.2 First trimester screening test 
Maternal serum triple marker test 
Among first trimester serum markers, pregnancy-associated plasma protein A (PAPP-A) 
and free ┚-hCG are known to have the highest discrimination for haploidy. In Down 
syndrome, the MoM of maternal serum PAPP-A is 0.38, decreasing by 60%, and that of free 
┚-hCG is 1.83, increasing by around two times.21 Accordingly, both of the two markers are 
used in first trimester screening, and with this test, the Down syndrome detection rate is 60-
74% and the false positive rate is 5%.19,20 The detection rate is lower than that of the quad 
test in the second trimester but similar to that of the triple test. 
Nuchal translucency measuring  
The thickness of nuchal translucency in the first trimester is related to fetal haploidy, in 
particular, to Down syndrome, apart from maternal serum markers.22 Accordingly, the 
accuracy of screening can be enhanced through the first trimester combined test that 
measures the thickness of nuchal translucency in addition to serologic tests that measure 
PAPPA-A and free ┚-hCG.22 In the results of a meta-analysis with 209,603 subjects, the 
combined screening test showed a detection rate of 86% (84-88 95%, CI) with a false positive 
rate of 5.1% and Down syndrome was detected in 785 subjects.23 When only nuchal 
translucency was measured without serologic tests, the Down syndrome detection rate was 
77% with a false positive rate of 6.0%, so it was less accurate than the combined test. The 
positive predictive value of the combined screening test was 16.8 (16.3-17.4, 95% CI), which 
means that one out of 17 pregnancies with a positive result of the combined screening test is 
found to have a Down syndrome fetus.23 On the other hand, because PAPP-A decreases but 
free ┚-hCG increases for 11-14 weeks of pregnancy, the detection rate varies significantly 
according to gestational age.23 In the results of FASTER, the Down syndrome detection rate 
was 73% and the false positive rate was 1% in 11 weeks of pregnancy, but 67% and 5%, 
respectively, in 13 weeks, and based on this result the research reported that the accuracy of 
the combined test was highest at the gestational age of 11 weeks.20 However, it was reported 
that if second trimester screening would be performed additionally, it would be more 
efficient to have the combined test in 10 weeks of pregnancy.23 
2.2.3 First and second trimester integrated test 
Wald et al.24 proposed integrated test, which uses information on first and second trimester 
markers in sequence. They expected that if nuchal translucency and serum PAPP-A are 
measured in 10-13 weeks, and alpha fetoprotein, total hCG, estriol and inhibin A in 15-18 
weeks, Down syndrome can be detected at a rate of 94% with a false positive rate of 5%, or 
85% with a false positive rate of 1%.25 Accordingly, because Down syndrome can be 
screened with a false positive rate of 1%, it reduces the need of additional diagnoses such as 
amniocentesis, and prevents fetal death resulting from invasive examination. In the results 
of SURUSS19 and FASTER,20 the integrated test was most accurate as a Down syndrome 
screening test (Table 3). 
However, the integrated test has a number of shortcomings to be an alternative general 
screening test in prenatal examination. First, most of pregnant women who receive a 
screening test in the first trimester want the termination of pregnancy immediately if 
abnormalities are found in the fetus, and it is safer to terminate pregnancy in the first 
trimester. Second, it is hard to distinguish pregnant women who cannot be followed up after 
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first trimester serologic tests. In SURUSS 19 as well, 20% of pregnant women who had a first 
trimester test did not appear in the second trimester test. In such a case, there could be the 
legal risk of not telling the results of the first trimester test, so it was not an adequate 
alternative at present. Third, if the risk is unusually high in the results of the first trimester 
test the results are not provided until the second trimester, and this may raise an ethical 
issue. Thus, the integrated test can be the method of highest sensitivity and specificity if a 
pregnant woman receives prenatal examination from the beginning of pregnancy and takes 
both the first and second trimester screening tests, but is not adequate for those who want to 
get invasive chorionic villus sampling immediately based on the results of the first trimester 
screening test. 
 
 FASTER20 SURUSS19 







FPR of    : 
 75% 85% 95% 1% 5% 75% 85% 95% 1% 5% 
1st trimester           
NT only 8.1 20 55 54 68 12.9 25 55 33 60 
PAPP-A + f-┚hCG 7.1 16 42 46 67 5.5 12.1 33 52 74 
Combined† 1.2 3.8 18 72 85 2.3 6.1 22 66 83 
1st + 2nd trimester:      .     
Serum integrated‡§ 1.2 3.6 15 70 86 0.8 2.7 12.5 77 90 
Full integrated§ 0.2 0.6 4.0 87 95 0.3 1.2 7.2 84 95 
2nd trimester           
Triple (AFP+hCG+E3) 7.0 14 32 45 69 2.9 7.1 22 51 74 
Quad (Triple+inhibin A) 3.1 7.3 22 60 81 2.6 6.1 18 63 83 
DR, detection rate; FPR, false positive rate; NT, nuchal translucency; PAPP-A, pregnancy associated 
plasma protein-A; f-┚hCG free beta subunit of human chorionic gonadotropin; Quad, second trimester 
quadruple screen; AFP, alphafetoprotein; uE3, unconjugated estriol 
† Combined: NT, PAPP-A, and f-┚hCG in the first trimester 
‡ Serum integrated: PAPP-A in the first trimester and quad screen in the second trimester 
§ Full integrated: NT and PAPP-A in the first trimester with quad screen in the second trimester 
Data from Rosen T et al. Semin Perinatol 2005;29:367-75. 
Table 3. Direct comparative data for the first and second trimester Down syndrome screens 
from the prospective FASTER and SURUSS trials. 
2.2.4 Alternatives to the integrated test 
Sequential screening 
If the result of the first trimester screening test is positive, chromosomal analysis is performed 
immediately and if the result is negative, the second trimester screening test is performed and 
if the result is positive, chromosomal analysis is performed. A characteristic of this method is 
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that the result of the first trimester screening test is provided to the pregnant woman and then 
the second trimester test is performed additionally. It can enhance the Down syndrome 
detection rate up to 98% but its false positive rate is also high as 17%.26 
Contingency screening 
If the first trimester screening test indicates high risk, chromosomal analysis is performed, 
and if the result indicates low risk no additional test is performed, but if it indicates 
moderate risk integrating screening is performed.27 
3. Genetic sonographic markers of aneuploidy 
Most of fetuses with chromosomal aberration have organs whose appearance is anomalous 
or abnormal, and such defects can be detected through prenatal sonography. A fetal 
structural anomaly may be caused by multiple factors, but it can be the result of 
chromosomal aberration. Therefore, if a fetal anomaly has been found, we should determine 
whether to perform cytogenetic analysis through amniocentesis after checking if other 
abnormalities accompany. Using genetic sonographic findings, we can detect pregnancies 
with high risk of aneuploidy at a sensitivity of 50-93%28, and the absence of genetic 
sonographic findings may be regarded as sure evidence for the low risk of haploidy. Genetic 
sonographic findings can be divided into major structural anomalies and minor anomalies. 
In particular, anomalies that are observed frequently also in normal fetuses and occasionally 
disappear with the advance of gestational age are called sonographic markers. It is generally 
accepted that a major anomaly is a sign of high risk of chromosomal aberration and thus 
chromosomal analysis is required, but it is still controversial whether additional tests are 
required when only a minor anomaly has been found. It is important to determine in 
consideration of the likelihood of chromosomal aberration on a case basis rather than 
applying a uniform rule to every case, and for this, we need to be familiar with the risk of 
chromosomal aberration and representative types of haploidy in connection to each genetic 
sonographic marker (Table 4).  
3.1 Major anomalies related to haploidy  
The characteristic and frequency of sonographic findings in fetuses with chromosomal 
aberration are various according to gestational age, and the detection of abnormal findings 
is affected by the reason of sonography, criteria for positive finding, the level of sonographic 
equipment, etc. Structural major anomalies are detected mostly by sonography in trisomy 13 
and 18, but are missed relatively often in trisomy 21. Table 5 summarized structural major 
anomalies detected commonly in pregnancies with trisomy 13, 18 and 21 and Turner 
syndrome. 
3.2 Sonographic markers related to haploidy  
The most common sonographic markers in the second trimester include nuchal thickening, 
hyperechoic bowel, short limbs, pyelectasia, echogenic intracardiac focus, and choroid 
plexus cysts. In general, the risk of chromosomal aberration is higher when the number of 
markers is large. Table 6 summarized the likelihood ratio of haploidy when each 
sonographic marker has occurred singly. The likelihood ratio was calculated by sensitivity / 
false positive rate, and if two or more sonographic markers have occurred together, the 
combined likelihood ratio is the product of their respective likelihood ratios.  
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Cystic hygroma 1/120 EU–1/6,000 B 60-75% 45X (80%),21,18,13,XXY 
Hydrops 1/1,500–4,000 B 30-80% 13,21,18,45X 
Hydrocephalus 3–8/10,000 LB 3-8% 13,18,triploidy 
Hydranencephaly 2/1,000 IA Minimal  
Holoprosencephaly 1/16,000 LB 40-60% 13,18,18p- 
Cardiac defect 7-9/100 LB 5-30% 21,18,13,22,8,9 
Diaphragmatic hernia 1/3,500–4,000 LB 20-25% 13,18,21,45X 
Omphalocele 1/5,800 LB 30-40% 13,18 
Gastroschisis 1/10,000–15,000 LB Minimal  
Duodenal atresia 1/10,000 LB 20-30% 21 
Bladder outlet obstruction 1-2/1,000 LB 20-25% 13,18 
Facial cleft 1/700 LB 1% 13,18, deletions 
Limb reduction 4-6/1,000 LB 8% 18 
Clubfoot 1.2/1,000 LB 20-30% 13,18, 4p-, 18q- 
Single umbilical artery 1% Minimal  
B, birth; EU, early ultrasonography; LB, livebirth; IA, infant autopsy. 
Data from Shipp TD, et al. Am J Obstet Gynecol 1998; 178: 600–2. and Nyberg DA and Crane JP. 
Chromosome abnormalities. In: Nyberg DA, et al. Diagnostic ultrasound of fetal anomalies: text and 
atlas. Chicago (IL): Year Book Medical; 1990. p. 676–724. 
Table 4. Aneuploidy risk of major structural fetal malformation. 
Aneuploidy Sonographic finding Aneuploidy Sonographic finding 




Face (midline defects, ocular 
abnormalities) 
Kidney(enlarged cystic kidneys)
IUGR with polyhydramnios 
Trisomy 21 Heart (septal defects) 
Abnormal fluid accumulation 
(thickened nuchal fold, cystic 
hygroma, fetal hydrops) 
Abdominal malformations 
IUGR with polyhydramnios 
Trisomy 18 Heart (VSD)
CNS (posterior fossa cyst, 
abnormal head shape, 
ventriculomegaly) 
Facial anomalies 
Choroid plexus cyst 
Abnormal fluid accumulation 
(thickened nuchal fold, cystic 
hygroma, fetal hydrops) 
Abdominal malformations 
IUGR with polyhydramnios 
Turner 
syndrome 
Heart (Coarctation of aorta) 
Abnormal fluid accumulation 
(increased nuchal 
translucency/ thickened 
nuchal fold, cystic hygroma, 
feta hydrops) 
Renal anomalies 
Short femur or humerus 
CNS, central nervous system; IUGR, intrauterine growth restriction; VSD, ventricular septal defect 
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 Likelihood ratio (95% confidence interval) 
Sonographic marker Nyberg et al. Smith-Bindman et al. 
Nuchal thickening 11.0 (5.5-22.0) 17 (8-38) 
Hyperechoic bowel 6.7 (2.7-16.8) 6.1 (3.0-12.6) 
Short humerus 5.1 (1.6-16.5) 7.5 (4.7-12.0) 
Short femur 1.5 (0.8-2.8) 2.7 (1.2-6.0) 
Echogenic intracardiac focus 1.8 (1.0-3.0) 2.8 (1.5-5.5) 
Pyelectasis 1.5 (0.6-3.6) 1.9 (0.7-5.1) 
Normal ultrasound 0.36 - 
Data from Nyberg DA, et al Ultrasound Obstet Gynecol 1998; 12: 8-14. and  
Smith-Bindman R et al. JAMA. 2001; 285: 1044-55. 
Table 6. Likelihood ratio of sonographic soft marker for fetal aneuploidy 
3.2.1 Choroid plexus cysts 
Choroid plexus cyst is found relatively commonly during the second trimester, showing a 
prevalence of 0.3-3.6%.29 This type of cyst is known to be benign, disappearing 
spontaneously at the later stage of pregnancy without affecting the development of the 
fetus. As a sonographic marker of haploidy, choroid plexus cyst is found in 50% of fetuses 
with trisomy 1830 but most of the cases are accompanied by another anomaly, and it is 
reported that no particular prenatal care including chromosomal analysis is necessary if 
only isolated choroid plexus cysts are found.29  
3.2.2 Mild cerebral ventricular dilatation 
Mild cerebral ventricular dilatation, in which the diameter of the cerebral lateral ventricle is 
over 10-15 mm, is related to aneuploidy like trisomy 21.32 Bromley et al.32 reported that 12% 
of pregnancies with mild cerebral ventricular dilatation are related to abnormal karyotype 
(trisomy 18, 21). In addition, mild cerebral ventricular dilatation was observed in 4.3% of 
fetuses with trisomy 2133 and all of them had accompanying anomalies. It is known that the 
presence of cerebral ventricular dilatation alone does not increase the risk of chromosomal 
aberration. 
3.2.3 Nuchal thickening 
Excessive skin on the back neck is a characteristic finding of trisomy 21. It is observed in 
80% of neonates with trisomy 21 and can be found in other chromosomal aberrations 
(trisomy 13 and 18, 45X).34 Although the sensitivity and the false positive rate vary 
according to gestational age and criteria for positive value are different among institutions, 
its sensitivity for detecting chromosomal aberrations is generally within the range of 20-40%. 
3.2.4 Hyper-echoic bowel 
Hyper-echoic bowel is found in 0.5% of normal fetuses, but in fetuses with aneuploidy like 
trisomy 21, it is known to be observed more frequently and increase the risk 6-7 times 
higher.35 Assuming that the likelihood ratio of isolated hyper-echoic bowel is 6.7 and the 
total risk of Down syndrome in the entire population is one per 500, isolated echoic bowel is 
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expected to be related to the risk of Down syndrome in around 1-2% of the general 
population. Hyper-echoic bowel is also known to be related to ileus, congenital infection, 
and rarely to secondary meconium ileus in cystic fibrosis.36 
3.2.5 Skeletal abnormalities such as shortened limbs 
Shortened limbs are a characteristic observed in fetuses with trisomy 2137 and the length of 
shortened humerus seems to be a slightly more specific marker than the length of shortened 
femur. These results may be different according to gestational age, racial group, expected 
sex of the fetus, and used criteria. 
3.2.6 Echogenic intracardiac focus 
Echogenic intracardiac focus is a common finding in the second trimester. It is observed in 
3-4% of normal fetuses and disappears spontaneously in the third trimester.39 If the size of 
echogenic intracardiac focus is large or there are multiple of them, the risk of aneuploidy 
increases. Bromley et al.40 reported that the risk of aneuploidy is 2 times higher when 
echogenic intracardiac focuses are in the right ventricle or bilateral than when they are only 
in the left ventricle. 
4. Conclusions 
Chromosomal aberration is closely related to the in intrauterine fetal death and perinatal 
prevalence. However, amniocentesis and chorionic villus sampling used for prenatal 
diagnosis of haploidy are invasive methods, and the reported fetal loss rate resulting just 
from the examinations is around 1-2%. Accordingly, it is very important to screen those with 
high risk of chromosomal aberration before such invasive examinations. 
Serologic test of pregnant women for the screening of trisomy 18 and 21 is an important 
diagnostic process in prenatal care, and in particular, second trimester serum alpha 
fetoprotein is used as an important screening marker to detect anomalies such as fetal neural 
tube defect. If the concentration of alpha fetoprotein is over 2.5 MoM, sonography should be 
performed in order to detect neural tube defect and other problems. Recently, because 
sonography shows a high detection rate for neural tube defect, amniocentesis is used less 
frequently in diagnosing neural tube defect. 
The preferred type of serum screening test is various among countries and institutions. In 
general, the first trimester screening test is increasingly preferred, but second trimester 
screening is still used frequently at hospitals that cannot measure fetal nuchal translucency 
or perform chorionic villus sampling. The triple test has been used commonly as second 
trimester screening, but recently the use of the quad test, which adds inhibin A, is 
increasing. If both first and second trimester tests are performed, they can increase the 
detection rate of fetal anomalies, but because the two tests have to be applied at an interval 
of 3-4 weeks, it is quite important to provide an adequate explanation to the patient. The 
serum screening test can be performed in various ways depending on the combination of 
serum factors. Thus, rather than using a uniform test for every case, we need to understand 
the characteristic, detection rate and false positive rate of each test, and individualize the test 
for each case according to maternal age, sonographic findings, and compliance. 
In conclusion, in order to determine the risk of chromosomal aberration, we should analyze 
each case based on maternal age, nuchal fold thickness in the first trimester, the results of 
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maternal serum screening in the first or second trimester, and sonographic findings in the 
second trimester. Through this approach, we may reduce the number of unnecessary 
chromosomal analyses, lower the fetal loss rate resulting from invasive examination, and 
enhance the accuracy of screening for fetal chromosomal aberrations.  
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